| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,950 | 6,750 | 20:54 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 9,500 | 175 | |||
| 8,550 | 450 | |||
| 6,750 | 1.182 | |||
| 6,700 | 71 | |||
| 6,600 | 71 | |||
| 6,500 | 673 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 602 | 6,150 | |||
| 71 | 6,100 | |||
| 71 | 6,000 | |||
| 1.182 | 5,950 | |||
| 71 | 5,900 | |||
| 700 | 4,740 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.697 | 0,987 | 2.661 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 28.10.2026 | 16:00:20 | 6,350 | 500 |
| Tagesumsatz Xetra | 0,000 0,00 % | 40 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | 4basebio Plc - Result of Retail Offer | 417 | PR Newswire | 4basebio Plc - Result of Retail OfferPR NewswireLONDON, United Kingdom, October 21
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 20.10. | 4basebio Plc - Posting of Circular and Notice of General Meeting | 349 | PR Newswire | 4basebio Plc - Posting of Circular and Notice of General MeetingPR NewswireLONDON, United Kingdom, October 20
20 October 2026
4basebio PLC
("4basebio" or the "Company")
Posting... ► Artikel lesen | |
| 15.10. | TRADING UPDATES: 4basebio fundraise; Geo Exploration secures grants | 4 | Alliance News | ||
| 15.10. | 4basebio Plc - Proposed Retail Offer | 576 | PR Newswire | 4basebio Plc - Proposed Retail OfferPR NewswireLONDON, United Kingdom, October 15
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS... ► Artikel lesen | |
| 15.10. | 4basebio Plc - Results of Capital Raise | 565 | PR Newswire | 4basebio Plc - Results of Capital RaisePR NewswireLONDON, United Kingdom, October 15
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 12:09 | Iovance Biotherapeutics Inc. - IOVA: weißer Rauch bei Lungenkrebs-Daten? | ratgeberGELD.at | Intraday Trade? Rekordumsatz in Q2 bei Iovance Biotherapeutics. Lifileucel-Therapie mit Mega-Marktpotenzial! Vorbörsliches Gap Up! Iovance Biotherapeutics (IOVA) - US4622601007 Rückblick Nach einer... ► Artikel lesen | |
| 11:10 | Moderna-Aktie: Kracht es am 6. November? | sharedeals.de | Moderna zählt 2026 mit mehr als 600% Kursgewinn zu den stärksten Aktien am Markt und hat sogar große KI-Konzerne deutlich übertroffen. Am 6. November könnten die Quartalszahlen neue Impulse liefern... ► Artikel lesen | |
| 12:03 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 18:02 | Market One Media Group Inc.: Market One Minute Feature on BNN Bloomberg: MustGrow Biologics and Bayer AG Discusses Validation of Its TerraMG Biocontrol Technology | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - October 29, 2026) - Market One ("Market One"), a marketing agency for public companies, shares editorial and video features on emerging growth stories... ► Artikel lesen | |
| 12:10 | Biogen Inc.: Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026 | GlobeNewswire (Europe) | Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's diseaseLecanemab... ► Artikel lesen |